Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)

被引：45

作者：

Fuchs, M. A. ^{[1
,2
]}

Yuan, C. ^{[1
,2
,3
]}

Sato, K. ^{[1
,2
]}

Niedzwiecki, D. ^{[4
]}

Ye, X. ^{[4
]}

Saltz, L. B. ^{[5
]}

Mayer, R. J. ^{[1
,2
]}

Mowat, R. B. ^{[6
]}

Whittom, R. ^{[7
]}

Hantel, A. ^{[8
]}

Benson, A. ^{[9
]}

Atienza, D. ^{[10
]}

Messino, M. ^{[11
]}

Kindler, H. ^{[12
]}

Venook, A. ^{[13
]}

Innocenti, F. ^{[14
]}

Warren, R. S. ^{[13
]}

Bertagnolli, M. M. ^{[1
,2
,15
]}

Ogino, S. ^{[1
,2
,3
,16
]}

Giovannucci, E. L. ^{[2
,3
,17
,18
]}

Horvath, E. ^{[19
]}

Meyerhardt, J. A. ^{[1
,2
]}

Ng, K. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Room D1220, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA USA

[3] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

[4] Duke Univ, Med Ctr, Alliance Stat & Data Ctr, Durham, NC 27706 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Toledo Community Hosp Oncol Program, Toledo, OH USA

[7] Hop Sacre Coeur, Montreal, PQ, Canada

[8] Edward Canc Ctr, Naperville, IL USA

[9] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[10] Virginia Oncol Associates, Norfolk, VA USA

[11] Southeast Canc Control Consortium, Mission Hosp Mem Campus, Asheville, NC USA

[12] Univ Chicago, Chicago, IL 60637 USA

[13] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[14] Univ North Carolina Chapel Hill, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA

[15] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA

[16] Brigham & Womens Hosp, Dept Pathol, Div MPE Mol Pathol Epidemiol, 75 Francis St, Boston, MA 02115 USA

[17] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA

[18] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA

[19] Alliance Protocol Operat Off, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷 / 06期

基金：

美国国家卫生研究院;

关键词：

colorectal neoplasm; vitamin D; survival analysis; prospective studies; COLORECTAL-CANCER; CARCINOMA-CELLS; D-3; CARCINOGENESIS; SURVIVAL; 1,25-DIHYDROXYVITAMIN-D3; INHIBITION; EXPRESSION; APOPTOSIS; RECEPTORS;

D O I：

10.1093/annonc/mdx109

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Observational studies suggest that higher levels of 25-hydroxyvitamin D-3 (25(OH) D) are associated with a reduced risk of colorectal cancer and improved survival of colorectal cancer patients. However, the influence of vitamin D status on cancer recurrence and survival of patients with stage III colon cancer is unknown. Patients and methods: We prospectively examined the influence of post-diagnosis predicted plasma 25(OH) D on outcome among 1016 patients with stage III colon cancer who were enrolled in a National Cancer Institute-sponsored adjuvant therapy trial (CALGB 89803). Predicted 25(OH) D scores were computed using validated regression models. We examined the influence of predicted 25(OH) D scores on cancer recurrence and mortality (disease-free survival; DFS) using Cox proportional hazards. Results: Patients in the highest quintile of predicted 25(OH) D score had an adjusted hazard ratio (HR) for colon cancer recurrence or mortality (DFS) of 0.62 (95% confidence interval [CI], 0.44-0.86), compared with those in the lowest quintile (P-trend = 0.005). Higher predicted 25(OH) D score was also associated with a significant improvement in recurrence-free survival and overall survival (P-trend = 0.01 and 0.0004, respectively). The benefit associated with higher predicted 25(OH) D score appeared consistent across predictors of cancer outcome and strata of molecular tumor characteristics, including microsatellite instability and KRAS, BRAF, PIK3CA, and TP53 mutation status. Conclusion: Higher predicted 25(OH) D levels after a diagnosis of stage III colon cancer may be associated with decreased recurrence and improved survival. Clinical trials assessing the benefit of vitamin D supplementation in the adjuvant setting are warranted.

引用

页码：1359 / 1367

页数：9

共 21 条

[1]

Díaz GD, 2000, CANCER RES, V60, P2304

[2]

Evans SRT, 2000, INT J ONCOL, V16, P1249

[3] 1α, 25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells [J].

Fernandez-Garcia, NI ;

Palmer, HG ;

Garcia, M ;

Gonzalez-Martin, A ;

del Rio, M ;

Barettino, D ;

Volpert, O ;

Muñoz, A ;

Jimenez, B .

ONCOGENE, 2005, 24 (43) :6533-6544

[4] Prospective study of predictors of vitamin D status and cancer incidence and mortality in men [J].

Giovannucci, E ;

Liu, Y ;

Rimm, EB ;

Hollis, BW ;

Fuchs, CS ;

Stampfer, MJ ;

Willett, WC .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (07) :451-459

[5]

Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5<730::AID-IJC11>3.0.CO

[6]

2-Q

[7] Vitamin D Receptor Deficiency Enhances Wnt/β-Catenin Signaling and Tumor Burden in Colon Cancer [J].

Jesus Larriba, Maria ;

Ordonez-Moran, Paloma ;

Chicote, Irene ;

Martin-Fernandez, Genesis ;

Puig, Isabel ;

Munoz, Alberto ;

Palmer, Hector G. .

PLOS ONE, 2011, 6 (08)

[8] Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis [J].

Lamprecht, SA ;

Lipkin, M .

CANCER PREVENTION: MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS, 2001, 952 :73-87

[9]

MEGGOUH F, 1991, CANCER RES, V51, P1227

[10] Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer [J].

Meyerhardt, Jeffrey A. ;

Niedzwiecki, Donna ;

Hollis, Donna ;

Saltz, Leonard B. ;

Hu, Frank B. ;

Mayer, Robert J. ;

Nelson, Heidi ;

Whittom, Renaud ;

Hantel, Alexander ;

Thomas, James ;

Fuchs, Charles S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (07) :754-764

← 1 2 3 →